D (3:03)

Well, it's affecting the candidates primarily on how they're going to spend the windfall of money that's going to come in over the next five years, something analysts estimate at around $41 billion. On the one hand, we have the current president of Guyana up for a second term, Irfan Ali of the People's Progressive Party. And he really wants to keep the deal with Exxon. Its partners the same. They want to keep their project going. And that's a project that is essentially driven by heavy spending on infrastructure, on building bridges, roads, schools, et cetera, and doing kind of public private partnerships to get this stuff built. In the opposition you have Aubrey Norton of the Partnership for National Unity Party or apnu. And what they're about is a much more kind of welfare state kind of model about getting money more directly into the pockets of the Guyanese, many of which are unhappy that they're not yet feeling the benefits of this oil boom.

B (4:13)

Okay, two part is two very different visions then. Any chance for a spoiler?

D (4:20)

There certainly is. Shaking up this duopoly is this new party called the WIN Party, which is led by a chap called Azreddin Mohammed. He's the son of one of Guyana's wealthiest men who made his millions in gold trading. And what Ezrad Mohammed is pledging is a sort of mix of economic populism. He also wants to renegotiate terms with Exxon. He's painting himself as a national unifier. He's drawing crowds. And while analysts aren't convinced he could win an outright majority with his party and become the president, there is a concern that his party could win a few seats and really disrupt things for whoever does win.

B (5:06)

And Jo, you spoke to someone who described this election as the mother of all elections. Why is this one so momentous?

D (5:14)

It's so momentous because the sheer size of revenues that are going to come in over the next five years are so enormous over the next presidential term. The amount of money coming in is potentially transformative. There's of course also the huge risk of so called resource curse of becoming so distorted by all these oil revenues that we start to see rampant corruption and a weakened economy in everything but oil and susceptible to global oil shocks. So the question as well of what's at stake is who manages this initial kind of development process for a country that I Repeat was the second poorest in the Americas just six years ago.

B (6:04)

Joe Daniels is the FT's Andean correspondent. Thanks Joe.

D (6:08)

Thank you.

B (6:13)

The UK has won a contract to supply Norway with at least five warships. The 10 billion pound deal is the largest ever for Britain's warship sector and the frigates will be built by BAE Systems in Glasgow. The new vessels are being built to counter Russian submarine activity in the Arctic and North Atlantic. Those two regions have become important theaters for NATO since Russia's full scale invasion of Ukraine in 2022. Just this past week, British, Norwegian and US forces have been actively monitoring a Russian submarine in the North Atlantic. That's according to the UK Ministry of Defence. BAE Systems is also helping to design and build warships for other UK allies like Canada and Australia. Less than A year ago, AstraZeneca's China division was embroiled in a scandal. There was a probe into alleged illegal drug sales and the then regional head was arrested. But today, the pharmaceuticals group's China business seems to have bounced back. Here to tell us how they managed the comeback is Eleanor Olcott. She covers China for the ft. Hi, Elena.

C (7:24)

Hi, Persis.

B (7:25)

Okay, so give me the backstory here. What's been going on with AstraZeneca in China?

C (7:31)

So AstraZeneca is the biggest global pharmaceutical company in China by sales. China is a very, very important market for the British drug maker. It's been very successful in China through various localization efforts and particularly kind of by investing a lot of authority in their very powerful former China boss, Leon Wang. And at the end of last year, Leon was arrested in Conn. This kind of probe into the alleged illegal importation and sale of a cancer drug in China. So this was a big, big shock for AstraZeneca. It was also a big shock for investors. Its share price fell by about 10% the day that news came out.

B (8:19)

Okay, and then what are the signs that the company has bounced back in China?

C (8:24)

Well, the first is pure numbers, right? So in the first half of the year, AstraZeneca sales in China were up 4%. That's not dramatic, but it's still significant given the backstory here. And the second indication is this kind of very politically significant meeting between AstraZeneca CEO Pascal Soriat. He was included in a group of CEOs who met with President Xi Jinping in March and photographed alongside the leader. Now, this group of individuals, the kind of list of attendees to this meeting is heavily, heavily scrutinized. And it's kind of in the grand theatre of CCP politics. It's very significant that AstraZeneca, especially having gone through this recent scandal in China, was included in this kind of very Elite list of CEOs chosen for this meeting with Xi Jinping.

B (9:21)

How has it managed this recovery? What has the strategy been to get back in Beijing's good Books.

C (9:27)

There's been a number of things that AstraZeneca has done in the immediate aftermath of the scandal, but really the most important thing that they've done is pledge $2.5 billion for a new research center in Beijing. Now, China is very, very keen for foreign companies to be investing in China. And so the fact that you've got such a huge investment in a strategically significant industry like bio tech, really, we've got a situation where AstraZeneca and the Chinese government's interests are aligned here. So I think really the politics around that investment have helped AstraZeneca to kind of ease their position and do a bit of good government relations in China.

B (10:18)

Okay, so AstraZeneca is doing well right now. Do you expect their China business to keep moving in the right direction?

C (10:25)

So AstraZeneca's got a pretty good pipeline of drugs. They also have been purchasing some innovative assets in China to kind of beef up their pipeline of new drugs. So it looks like they're in a good position. I would just add here that this has been a very difficult time for AstraZeneca employees in China. We spoke to one employee who talked about how difficult the environment had been. I mean, Leon's presence still looms large over the company. So I think. I think that part of the puzzle has still not yet been answered by the new leadership team. But that shouldn't be a kind of existential issue.

B (11:05)

That's the FT's Elena Olcott in Beijing. Thanks, Elena.

C (11:09)

Thank you.

B (11:11)

You can read more on all these stories for free when you click on the links in our show notes. This has been your daily FT news briefing. Check back tomorrow for the latest business news.

C (11:37)

Thinking long term about your investment career? Hear stories, advice and lessons from seasoned.

D (11:43)

Leaders at Capital Group on the Capital Ideas podcast. Subscribe and start listening today. Published by Capital Client Group Inc.

A (11:51)

Flowers die in three days. Matching underwear from Meundies. That's a gift that lasts. Meundies creates matching prints for couples and friends. Same adorable designs in different cuts for each of you. All made from their signature ultramodal fabric that feels impossibly soft. With 30 million pairs sold and 90,000 five star reviews, Meundi's matching prints are the perfect gift. Valentine's Day is February 14th, so don't wait. Get exclusive deals up to 50% off at Meundies.com acast code acast that's Meundies.com acast Code acast.